Related Experiment Video
Updated: Nov 21, 2025
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Molecular Epidemiology of the Main Druggable Genetic Alterations in Non-Small Cell Lung Cancer
Sara S Fois1, Panagiotis Paliogiannis1, Angelo Zinellu2
1Department of Medical, Surgical and Experimental Sciences, University of Sassari, Viale San Pietro 43, 07100 Sassari, Italy.
Abstract:
Lung cancer is the leading cause of death for malignancy worldwide. Its molecular profiling has enriched our understanding of cancer initiation and progression and has become fundamental to provide guidance on treatment with targeted therapies. Testing the presence of driver mutations in specific genes in lung tumors has thus radically changed the clinical management and outcomes of the disease. Numerous studies performed with traditional sequencing methods have investigated the occurrence of such mutations in lung cancer, and new insights regarding their frequency and clinical significance are continuously provided with the use of last generation sequencing technologies. In this review, we discuss the molecular epidemiology of the main druggable genetic alterations in non-small cell lung cancer, namely EGFR, KRAS, BRAF, MET, and HER2 mutations or amplification, as well as ALK and ROS1 fusions. Furthermore, we investigated the predictive impact of these alterations on the outcomes of modern targeted therapies, their global prognostic significance, and their mutual interaction in cases of co-occurrence.
Insights
This review details key genetic alterations in non-small cell lung cancer (NSCLC), including EGFR and KRAS mutations. Understanding these driver mutations is crucial for effective targeted therapy selection and improved patient outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Lung cancer remains a leading global cause of cancer death.
- Molecular profiling has transformed understanding of cancer and personalized treatment strategies.
- Targeted therapies, guided by specific genetic alterations, have improved clinical management and patient outcomes.
Purpose of the Study:
- To review the molecular epidemiology of key druggable genetic alterations in non-small cell lung cancer (NSCLC).
- To discuss the predictive impact of these alterations on targeted therapy outcomes.
- To explore the prognostic significance and co-occurrence interactions of these genetic alterations.
Main Methods:
- Review of numerous studies utilizing traditional and next-generation sequencing technologies.
- Analysis of molecular epidemiology data for specific gene mutations and fusions in NSCLC.
- Investigation of clinical significance and predictive value of genetic alterations in targeted therapy.
Main Results:
- Identified main druggable genetic alterations in NSCLC: EGFR, KRAS, BRAF, MET, HER2 mutations/amplifications, and ALK, ROS1 fusions.
- Highlighted the critical role of these alterations in guiding targeted therapy selection.
- Emphasized the impact of these genetic profiles on patient prognosis and treatment response.
Conclusions:
- Molecular profiling of NSCLC is fundamental for personalized medicine and targeted treatment selection.
- Understanding the landscape of genetic alterations, their frequency, and clinical impact is essential for optimizing lung cancer care.
- Further research into co-occurring mutations and their interactions will refine therapeutic strategies.
More Related Videos
11:15Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
Published on: September 20, 2016
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
Related Concept Videos
02:18Cancer
02:56Treatment Resistant Cancers